IL93576A - Pharmaceutical compositions of 4-phenyl-1,2,3, 4-tetrahydro-1-naphthalamine used to treat psychosis, inflammation and as immunosuppressants - Google Patents
Pharmaceutical compositions of 4-phenyl-1,2,3, 4-tetrahydro-1-naphthalamine used to treat psychosis, inflammation and as immunosuppressantsInfo
- Publication number
- IL93576A IL93576A IL9357690A IL9357690A IL93576A IL 93576 A IL93576 A IL 93576A IL 9357690 A IL9357690 A IL 9357690A IL 9357690 A IL9357690 A IL 9357690A IL 93576 A IL93576 A IL 93576A
- Authority
- IL
- Israel
- Prior art keywords
- tetrahydro
- naphthalenamine
- cis
- inflammation
- psychosis
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 17
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 17
- 208000028017 Psychotic disease Diseases 0.000 title claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 15
- 229960003444 immunosuppressant agent Drugs 0.000 title description 6
- 239000003018 immunosuppressive agent Substances 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 33
- 230000001506 immunosuppresive effect Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- 206010062016 Immunosuppression Diseases 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000001246 bromo group Chemical group Br* 0.000 claims description 6
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- VGKDLMBJGBXTGI-RGUGMKFQSA-N (1r)-4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C([C@H](C1=CC=CC=C11)NC)CC1C1=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-RGUGMKFQSA-N 0.000 claims description 3
- VGKDLMBJGBXTGI-YVEFUNNKSA-N (1r,4s)-4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@@H]2CC[C@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-YVEFUNNKSA-N 0.000 claims description 3
- SBRLSQHYWNDGMV-NSHDSACASA-N (4s)-4-(3,4-dichlorophenyl)-3,4-dihydro-2h-naphthalene-1,1-diamine Chemical compound C1([C@@H]2CCC(C3=CC=CC=C32)(N)N)=CC=C(Cl)C(Cl)=C1 SBRLSQHYWNDGMV-NSHDSACASA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 230000000561 anti-psychotic effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- LTKRQOGLVNJKBK-FVRDMJKUSA-N (4s)-4-(3,4-dichlorophenyl)-n,n-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@@H]2CCC(C3=CC=CC=C32)N(C)C)=CC=C(Cl)C(Cl)=C1 LTKRQOGLVNJKBK-FVRDMJKUSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- LLMOMOOMHWFGRN-MBIQTGHCSA-N (4s)-4-(4-chlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@@H]2CCC(C3=CC=CC=C32)NC)=CC=C(Cl)C=C1 LLMOMOOMHWFGRN-MBIQTGHCSA-N 0.000 claims 2
- VGKDLMBJGBXTGI-SJKOYZFVSA-N (1r,4r)-4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@H]2CC[C@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJKOYZFVSA-N 0.000 claims 1
- VGKDLMBJGBXTGI-MTATWXBHSA-N (4r)-4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@H]2CCC(C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-MTATWXBHSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- IWNWWVPLTTUPBQ-UHFFFAOYSA-N 4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C12=CC=CC=C2C(N)CCC1C1=CC=CC=C1 IWNWWVPLTTUPBQ-UHFFFAOYSA-N 0.000 abstract description 4
- 230000027455 binding Effects 0.000 description 10
- HTSNFXAICLXZMA-UHFFFAOYSA-N 3-(1-propyl-3-piperidinyl)phenol Chemical compound C1N(CCC)CCCC1C1=CC=CC(O)=C1 HTSNFXAICLXZMA-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108010085082 sigma receptors Proteins 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- FTHCZYMFYCBWMW-UHFFFAOYSA-N Cl.CNCO.CNCO.CNCO Chemical compound Cl.CNCO.CNCO.CNCO FTHCZYMFYCBWMW-UHFFFAOYSA-N 0.000 description 1
- 206010014557 Emotional poverty Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/320,014 US4981870A (en) | 1989-03-07 | 1989-03-07 | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL93576A0 IL93576A0 (en) | 1990-11-29 |
| IL93576A true IL93576A (en) | 1995-12-08 |
Family
ID=23244506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9357690A IL93576A (en) | 1989-03-07 | 1990-02-28 | Pharmaceutical compositions of 4-phenyl-1,2,3, 4-tetrahydro-1-naphthalamine used to treat psychosis, inflammation and as immunosuppressants |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US4981870A (de) |
| EP (1) | EP0386997B1 (de) |
| JP (2) | JPH0714870B2 (de) |
| KR (1) | KR920005810B1 (de) |
| AT (1) | ATE150299T1 (de) |
| AU (1) | AU610036B2 (de) |
| CA (1) | CA2011428C (de) |
| DE (1) | DE69030212T2 (de) |
| DK (1) | DK0386997T3 (de) |
| HU (1) | HU221624B1 (de) |
| IE (1) | IE81047B1 (de) |
| IL (1) | IL93576A (de) |
| MY (1) | MY106272A (de) |
| NZ (1) | NZ232800A (de) |
| PH (1) | PH26542A (de) |
| PT (1) | PT93351B (de) |
| ZA (1) | ZA901743B (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
| CA2071897A1 (en) * | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| ES2060547B1 (es) * | 1992-06-04 | 1995-06-16 | Ferrer Int | Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina". |
| ZA944513B (en) * | 1993-06-23 | 1996-01-16 | Cambridge Neuroscience Inc | Sigma receptor ligands |
| ES2074946B1 (es) * | 1993-07-19 | 1996-06-16 | Ferrer Int | Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida. |
| US20040208926A1 (en) * | 1997-07-01 | 2004-10-21 | Pfizer Inc | Solubilized sertraline compositions |
| US20030133974A1 (en) * | 1997-07-01 | 2003-07-17 | Curatolo William John | Encapsulated solution dosage forms of sertraline |
| CA2290966C (en) | 1997-07-01 | 2005-12-20 | Pfizer Inc. | Sertraline salts and sustained-release dosage forms of sertraline |
| JP2003518487A (ja) | 1999-12-23 | 2003-06-10 | ファイザー・プロダクツ・インク | ヒドロゲル駆動型積層薬物製剤 |
| AU2002322720B2 (en) | 2001-07-25 | 2008-11-13 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US6988556B2 (en) * | 2002-02-19 | 2006-01-24 | Halliburton Energy Services, Inc. | Deep set safety valve |
| WO2004024130A2 (en) * | 2002-09-16 | 2004-03-25 | Sepracor, Inc. | TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE |
| US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| CN100584818C (zh) * | 2002-09-16 | 2010-01-27 | 塞普拉科公司 | 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症 |
| JP4610336B2 (ja) * | 2002-09-16 | 2011-01-12 | セプラコール インク． | トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミン及びそのホルムアミドによる中枢神経系障害の治療 |
| US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| AU2004312530A1 (en) * | 2003-12-29 | 2005-07-21 | Sepracor Inc. | Pyrrole and pyrazole DAAO inhibitors |
| CA2789262C (en) | 2005-04-28 | 2016-10-04 | Proteus Digital Health, Inc. | Pharma-informatics system |
| JP2009500425A (ja) | 2005-07-06 | 2009-01-08 | セプラコア インコーポレーテッド | エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法 |
| EP1940389A2 (de) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation von neurogenese durch pde-hemmung |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| BRPI0706365A2 (pt) | 2006-01-06 | 2011-03-22 | Sepracor Inc | Cicloalquilaminas como inibidores da recaptação de monoamina |
| NZ569608A (en) * | 2006-01-06 | 2011-09-30 | Sepracor Inc | Tetralone-based monoamine reuptake inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| DK2816024T3 (en) | 2006-03-31 | 2017-10-30 | Sunovion Pharmaceuticals Inc | CHIRALE AMINER |
| JP2009536667A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | ５ｈｔ受容体介在性の神経新生 |
| EP2382975A3 (de) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
| AU2007254751A1 (en) * | 2006-05-31 | 2007-12-13 | Sepracor Inc. | Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide |
| US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
| US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| EP2063905B1 (de) | 2006-09-18 | 2014-07-30 | Raptor Pharmaceutical Inc | Behandlungen von lebererkrankungen durch verabreichung von konjugaten aus rezeptor-assoziierten proteinen |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20080082066A1 (en) * | 2006-10-02 | 2008-04-03 | Weyerhaeuser Co. | Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks |
| FR2909376A1 (fr) * | 2006-11-30 | 2008-06-06 | Cerep Sa | Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables |
| US20090099248A1 (en) * | 2007-01-18 | 2009-04-16 | Sepracor Inc. | Inhibitors of d-amino acid oxidase |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| AU2008259841B2 (en) | 2007-05-31 | 2015-02-05 | Sunovion Pharmaceuticals Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
| WO2010017418A1 (en) * | 2008-08-07 | 2010-02-11 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| KR101909711B1 (ko) | 2009-05-06 | 2018-12-19 | 라보라토리 스킨 케어, 인크. | 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법 |
| WO2011017634A2 (en) * | 2009-08-07 | 2011-02-10 | Sepracore Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| JP6433482B2 (ja) | 2013-03-15 | 2018-12-05 | エージンバイオ， インコーポレイテッド | 認知機能を改善するための方法および組成物 |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| CA2948839A1 (en) * | 2014-05-13 | 2015-11-19 | Sunovion Pharmaceuticals Inc. | Dosage of dasotraline and method for treatment of adhd |
| US20170266133A1 (en) * | 2014-05-13 | 2017-09-21 | Sunovion Pharmaceuticals Inc. | Methods and compositions of dasotraline for treatment of adhd |
| WO2016046669A2 (en) * | 2014-09-27 | 2016-03-31 | Mohan M Alapati | Compositions and methods for the treatment of depression and neurological diseases |
| WO2016191288A1 (en) | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| FR3071726B1 (fr) * | 2017-09-29 | 2020-09-04 | Univ Paris Sud | Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1420472A (en) * | 1972-09-27 | 1976-01-07 | Pfizer | Aminophenyltetralin compounds |
| US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| JPS59497B2 (ja) * | 1979-11-01 | 1984-01-07 | フアイザ−・インコ−ポレ−テツド | トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体 |
| US4792448A (en) * | 1987-06-11 | 1988-12-20 | Pfizer Inc. | Generic zero order controlled drug delivery system |
| US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
-
1989
- 1989-03-07 US US07/320,014 patent/US4981870A/en not_active Expired - Lifetime
-
1990
- 1990-02-28 IL IL9357690A patent/IL93576A/en not_active IP Right Cessation
- 1990-03-05 CA CA002011428A patent/CA2011428C/en not_active Expired - Fee Related
- 1990-03-05 MY MYPI90000347A patent/MY106272A/en unknown
- 1990-03-06 PT PT93351A patent/PT93351B/pt not_active IP Right Cessation
- 1990-03-06 EP EP90302365A patent/EP0386997B1/de not_active Expired - Lifetime
- 1990-03-06 DE DE69030212T patent/DE69030212T2/de not_active Expired - Fee Related
- 1990-03-06 NZ NZ232800A patent/NZ232800A/en unknown
- 1990-03-06 JP JP2054802A patent/JPH0714870B2/ja not_active Expired - Fee Related
- 1990-03-06 AU AU50796/90A patent/AU610036B2/en not_active Ceased
- 1990-03-06 KR KR1019900002912A patent/KR920005810B1/ko not_active Expired
- 1990-03-06 AT AT90302365T patent/ATE150299T1/de not_active IP Right Cessation
- 1990-03-06 DK DK90302365.3T patent/DK0386997T3/da active
- 1990-03-06 HU HU9001325A patent/HU221624B1/hu not_active IP Right Cessation
- 1990-03-07 IE IE79890A patent/IE81047B1/en not_active IP Right Cessation
- 1990-03-07 PH PH40157A patent/PH26542A/en unknown
- 1990-03-07 ZA ZA901743A patent/ZA901743B/xx unknown
- 1990-12-05 US US07/622,308 patent/US5061728A/en not_active Expired - Lifetime
-
1994
- 1994-07-25 JP JP6172929A patent/JP3020808B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0386997A3 (de) | 1992-04-29 |
| AU5079690A (en) | 1990-09-20 |
| PT93351B (pt) | 1996-03-29 |
| IL93576A0 (en) | 1990-11-29 |
| MY106272A (en) | 1995-04-29 |
| CA2011428C (en) | 1994-11-08 |
| JP3020808B2 (ja) | 2000-03-15 |
| DE69030212D1 (de) | 1997-04-24 |
| JPH07173056A (ja) | 1995-07-11 |
| PH26542A (en) | 1992-08-19 |
| PT93351A (pt) | 1990-11-07 |
| AU610036B2 (en) | 1991-05-09 |
| IE81047B1 (en) | 1999-12-01 |
| KR900013949A (ko) | 1990-10-22 |
| JPH0714870B2 (ja) | 1995-02-22 |
| ATE150299T1 (de) | 1997-04-15 |
| ZA901743B (en) | 1991-10-30 |
| US5061728A (en) | 1991-10-29 |
| JPH02300121A (ja) | 1990-12-12 |
| HUT59000A (en) | 1992-04-28 |
| IE900798L (en) | 1990-09-07 |
| DE69030212T2 (de) | 1997-06-26 |
| KR920005810B1 (ko) | 1992-07-20 |
| US4981870A (en) | 1991-01-01 |
| NZ232800A (en) | 1997-07-27 |
| EP0386997A2 (de) | 1990-09-12 |
| HU901325D0 (en) | 1990-05-28 |
| DK0386997T3 (da) | 1997-04-14 |
| EP0386997B1 (de) | 1997-03-19 |
| CA2011428A1 (en) | 1990-09-07 |
| HU221624B1 (hu) | 2002-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5061728A (en) | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of inflammation and as immunosuppressants | |
| DE69233462T2 (de) | Zusammensetzung die Tramadol und ein nichtsteroides entzündungshemmenden Mittel enthält | |
| NZ198953A (en) | (-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine,its salts and pharmaceutical formulations | |
| HU226138B1 (en) | R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof | |
| IE63511B1 (en) | Medicament | |
| CA2138998A1 (en) | Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine | |
| SK13862001A3 (sk) | Použitie zlúčeniny pri výrobe liečivá na liečenie neurologických alebo neuropsychiatrických porúch | |
| CA2139000A1 (en) | Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine | |
| EA015566B1 (ru) | Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая | |
| AU608922B2 (en) | Method for the treatment of anxiety | |
| JPH05132430A (ja) | 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法 | |
| WO2003002059A2 (en) | Tolterodine metabolites | |
| Wei et al. | Stereoselective disposition of hydroxychloroquine and its metabolites in rats | |
| US6552087B1 (en) | Therapeutic agent comprising (+)-sibutramine | |
| CA2168265C (en) | Antidepressant | |
| US4053637A (en) | Compounds of diphenylcyclopentylamine type and methods for their uses | |
| US4963545A (en) | Benzothiazepine anti-seizure method | |
| US4141993A (en) | Compounds of diphenylcyclopentylamine type and methods for their preparation | |
| SK283205B6 (sk) | Použitie selegilínu na ošetrovanie epileptických ochorení | |
| Kinoshita et al. | Effects of vinconate on spatial learning impairments induced by medial septal lesion in rats | |
| DE3686538T2 (de) | Verwendung von dibenz(cd,f)indol-derivaten zur praevention vom alkoholmissbrauch. | |
| US3772440A (en) | Method for the treatment of parkinsonism and depression | |
| Wong et al. | Fluoxetine (Prozac) and Other Selective Serotonin Uptake Inhibitors | |
| Wong et al. | DEVELOPMENT OF ANTIDEPRESSANT DRUGS | |
| KR20010071780A (ko) | Ｇａｂａ 유사체에 의한 신산통의 치료 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees | ||
| MM9K | Patent not in force due to non-payment of renewal fees |